PHILADELPHIA – Impairment is detected at 1.5 hours after dosing and is resolved by 8 hours after dosing.
PHILADELPHIA – Results from a pair of dose-ranging, randomized studies showed one IV eptinezumab dose cut migraine recurrences for 3 months.
The association was significant in those with effective glycemic control.
News from the FDA/CDC
Despite increases in the number of naloxone prescriptions dispensed, many patients at risk for overdose are not offered the potentially life-...
LOS ANGELES – The drugs were not associated with Alzheimer’s pathology, but were associated with a trend toward greater loss of neurons in the...
Topics include: Smoking cessation & RA • Pregnancy loss after stillbirth • Biomarker for dementia? • MI & stroke post-cancer Dx •...
The American Medical Society for Sports Medicine recommends that student athletes receive specific evaluations.
Sexual dysfunction is one of the “invisible symptoms” of MS. Identifying the underlying cause can guide treatment choices for your patient.
PHILADELPHIA – Results from a U.S. survey showed an 18% prevalence of medication overuse among people with self-reported migraine symptoms.